Literature DB >> 9624509

Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

T Schülin1, C B Wennersten, M J Ferraro, R C Moellering, G M Eliopoulos.   

Abstract

The in vitro activities of 13 antimicrobial agents against 30 strains of Legionella spp. were determined. Rifapentine, rifampin, and clarithromycin were the most potent agents (MICs at which 90% of isolates are inhibited [MIC90s], < or = 0.008 microgram/ml). The ketolide HMR 3647 and the fluoroquinolones levofloxacin and BAY 12-8039 (MIC90s, 0.03 to 0.06 microgram/ml) were more active than erythromycin A or roxithromycin. The MIC90s of dalfopristin-quinupristin and linezolid were 0.5 and 8 micrograms/ml, respectively. Based on class characteristics and in vitro activities, several of these agents may have potential roles in the treatment of Legionella infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624509      PMCID: PMC105637     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.

Authors:  E O Mason; L B Lamberth; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

2.  Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.

Authors:  S L Pendland; S J Martin; C Chen; P C Schreckenberger; L H Danziger
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

Review 3.  Legionellosis.

Authors:  J E Stout; V L Yu
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

Review 4.  Antimicrobial chemotherapy for legionnaires' disease: a review.

Authors:  P H Edelstein
Journal:  Clin Infect Dis       Date:  1995-12       Impact factor: 9.079

5.  In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; K H Lehr; J Ren
Journal:  J Antimicrob Chemother       Date:  1996-01       Impact factor: 5.790

6.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

7.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

8.  Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.

Authors:  I Herrera-Insúa; K Jacques-Palaz; B E Murray; R M Rakita
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Susceptibility of Legionella pneumophila to twenty antimicrobial agents.

Authors:  P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

View more
  27 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.

Authors:  Jun-Ichi Kadota; Yuji Ishimatsu; Tetsuji Iwashita; Yuichi Matsubara; Kazunori Tomono; Masao Tateno; Roza Ishihara; Claudette Muller-Serieys; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Legionella.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

5.  Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Authors:  M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 6.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis.

Authors:  J M Rolain; M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

9.  Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Authors:  C Muller-Serieys; P Soler; C Cantalloube; F Lemaitre; H P Gia; F Brunner; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.